Skip to main content Accessibility help

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

  • Stuart H. Cohen (a1), Dale N. Gerding (a2), Stuart Johnson (a2), Ciaran P. Kelly (a3), Vivian G. Loo (a4), L. Clifford McDonald (a5), Jacques Pepin (a6) and Mark H. Wilcox (a7)...


Since publication of the Society for Healthcare Epidemiology of America position paper on Clostridium difficile infection in 1995, significant changes have occurred in the epidemiology and treatment of this infection. C. difficile remains the most important cause of healthcare-associated diarrhea and is increasingly important as a community pathogen. A more virulent strain of C. difficile has been identified and has been responsible for more-severe cases of disease worldwide. Data reporting the decreased effectiveness of metronidazole in the treatment of severe disease have been published. Despite the increasing quantity of data available, areas of controversy still exist. This guideline updates recommendations regarding epidemiology, diagnosis, treatment, and infection control and environmental management.



Hide All
1.McFarland, LV, Mulligan, ME, Kwok, RY, et al.Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204210.
2.Shanholtzer, CJ, Willard, KE, Holter, JJ, et al.Comparison of the VIDAS Clostridium difficile toxin A immunoassay with C. difficile culture and cytotoxin and latex tests. J Clin Microbiol 1992;30:18371840.
3.Shim, JK, Johnson, S, Samore, MH, et al.Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351:633636.
4.Walker, RC, Ruane, PJ, Rosenblatt, JE, et al.Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis 1986;5:6169.
5.Kyne, L, Warny, M, Qamar, A, et al.Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342:390397.
6.Louie, TJ, Peppe, J, Watt, CK, et al.Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:411420.
7.Musher, DM, Logan, N, Hamill, RJ, et al.Nitazoxanide for the treatment of Clostridium diffidle colitis. Clin Infect Dis 2006;43:421427.
8.Kuijper, EJ, Coignard, B, Tuli, P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12(Suppl 6):218.
9.Gerding, DN, Olson, MM, Peterson, LR, et al.Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986;146:95100.
10.Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388416.
11.Kyne, L, Merry, C, O'Connell, B, et al.Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999;28:107113.
12.Bartlett, JG. Antibiotic-associated colitis. Dis Mon 1984;30:154.
13.Bartlett, JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334349.
14.Kelly, CP, Pothoulakis, C, LaMont, JT. Clostridium diffidle colitis. N Engl J Med 1994;330:257262.
15.Hall, IC, O'Toole, E. Intestinal flora in new-born infants. Am J Dis Child 1935;49:390402.
16.Viscidi, R, Willey, S, Bartlett, JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81:59.
17.Aronsson, B, Mollby, R, Nord, CE. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. J Infect Dis 1985;151:476481.
18.Nakamura, S, Mikawa, M, Nakashio, S, et al.Isolation of Clostridium diffidle from the feces and the antibody in sera of young and elderly adults. Microbiol Immunol 1981;25:345351.
19.Burdon, DW. Clostridium difficile, the epidemiology and prevention of hospital-acquired infection. Infection 1982;10:203204.
20.Larson, HE, Barclay, FE, Honour, P, et al.Epidemiology of Clostridium diffidle in infants. J Infect Dis 1982;146:727733.
21.Larson, HE, Price, AB, Bordello, SP. Epidemiology of experimental en-terocecitis due to Clostridium difficile. J Infect Dis 1980;142:408413.
22.Toshniwal, R, Silva, J Jr, Fekety, R, et al.Studies on the epidemiology of colitis due to Clostridium difficile in hamsters. J Infect Dis 1981;143:5154.
23.Johnson, S, Clabots, CR, Linn, FV, et al.Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97100.
24.McDonald, LC, Killgore, GE, Thompson, A, et al.An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005;353:24332441.
25.Loo, VG, Poirier, L, Miller, MA, et al.A predominantly clonal multi-institutional outbreak of Clostridium diffidle-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:24422449.
26.Voth, DE, Ballard, JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247263.
27.Samore, MH, DeGirolami, PC, Tlucko, A, et al.Clostridium diffidle colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994;18:181187.
28.Olson, MM, Shanholtzer, CJ, Lee, JT Jr, et al.Ten years of prospective Clostridium diffidle-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371381.
29.Triadafilopoulos, G, Hailstone, AE. Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology 1991;101:685691.
30.Wolf, LE, Gorbach, SL, Granowitz, EV. Extraintestinal Clostridium difficile: 10 years' experience at a tertiary-care hospital. Mayo Clin Proc 1998;73:943947.
31.Pron, B, Merckx, J, Touzet, P, et al.Chronic septic arthritis and osteomyelitis in a prosthetic knee joint due to Clostridium difficile. Eur J Clin Microbiol Infect Dis 1995;14:599601.
32.Studemeister, AE, Beilke, MA, Kirmani, N. Splenic abscess due to Clostridium difficile and Pseudomonas paucimobilis. Am J Gastroenterol 1987;82:389390.
33.Feldman, RJ, Kallich, M, Weinstein, MP. Bacteremia due to Clostridium difficile: case report and review of extraintestinal C. difficile infections. Clin Infect Dis 1995;20:15601562.
34.Freiler, JF, Durning, SJ, Ender, PT. Clostridium diffidle small bowel enteritis occurring after total colectomy. Clin Infect Dis 2001;33:14291431.
35.Wanahita, A, Goldsmith, EA, Marino, BJ, et al.Clostridium diffidle infection in patients with unexplained leukocytosis. Am J Med 2003;115:543546.
36.Wanahita, A, Goldsmith, EA, Musher, DM. Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by Clostridium difficile. Clin Infect Dis 2002;34:15851592.
37.Gerding, DN, Johnson, S, Peterson, LR, et al.Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459477.
38.Field, MJ, Lohr, KN. Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice Guidelines, Clinical Practice Guidelines: Directions for a New Program. Washington, DC: Institute of Medicine; 1990.
39.The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979;121:11931254.
40.Miller, MA, Hyland, M, Ofher-Agostini, M, et al.Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 2002;23:137140.
41.Miller, MA, Gravel, D, Mulvey, M, et al.Surveillance for nosocomial Clostridium difficile associated diarrhea (N-CDAD) within acute-care hospitals in Canada: results of the 2005 nosocomial infections surveillance program (CNISP) study shows escalating mortality. In: Proceedings of the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL.
42.Walker, KJ, Gilliland, SS, Vance-Bryan, K, et al.Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc 1993;41:940946.
43.Simor, AE, Bradley, SF, Strausbaugh, LJ, et al.Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 2002;23:696703.
44.Kyne, L, Hamel, MB, Polavaram, R, et al.Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346353.
45.O'Brien, JA, Lahue, BJ, Caro, JJ, et al.The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:12191227.
46.McDonald, LC, Owings, M, Jernigan, DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409415.
47.Pepin, J, Alary, ME, Valiquette, L, et al.Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:15911597.
48.Muto, CA, Pokrywka, M, Shutt, K, et al.A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273280.
49. Centers for Disease Control and Prevention. Data and statistics about Clostridium difficile infections Web page, Accessed February 22, 2010.
50.Eggertson, L. Quebec strain of C. difficile in 7 provinces. Can Med Assoc 2006;174:607608.
51.Warny, M, Pepin, J, Fang, A, et al.Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:10791084.
52.Health Protection Agency. Outbreak of Clostridium difficile infection in a hospital in southeast England. CDR Weekly 2005;15(24).
53.Kuijper, EJ, Debast, SB, Van Kregten, E, et al.Clostridium difficile ribo-type 027, toxinotype III in The Netherlands [in Dutch]. Ned Tijdschr Geneeskd 2005;149:20872089.
54.Kuijper, EJ, Barbut, F, Brazier, JS, et al.Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;13(31):pii:18942.
55.Kato, H, Ito, Y, van den Berg, RJ, et al.First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007;12:E0701113.
56.Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR Morb Mortal Wkly Rep 2005;54:12011205.
57.James, AH, Katz, VL, Dotters, DJ, et al.Clostridium difficile infection in obstetric and gynecologic patients. South Med J 1997;90:889892.
58.Kyne, L, Merry, C, O'Connell, B, et al.Community-acquired Clostridium diffidle infection. J Infect 1998;36:287288.
59.Johal, SS, Hammond, J, Solomon, K, et al.Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673677.
60.Terhes, G, Urban, E, Sold, J, et al.Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 2004;42:43164318.
61.Dial, S, Delaney, JA, Barkun, AN, et al.Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium diffidle-associated disease. JAMA 2005;294:29892995.
62.Hirschhorn, LR, Trnka, Y, Onderdonk, A, et al.Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127133.
63.Levy, DG, Stergachis, A, McFarland, LV, et al.Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther 2000;22:91102.
64.Frost, F, Hurley, JS, Petersen, HV, et al.Estimated incidence of Clostridium difficile infection. Emerg Infect Dis 1999;5:303304.
65.Rivera, EV, Woods, S. Prevalence of asymptomatic Clostridium difficile colonization in a nursing home population: a cross-sectional study. J Gend Specif Med 2003;6:2730.
66.Fekety, R, Kim, KH, Brown, D, et al.Epidemiology of antibiotic-associated colitis: isolation of Clostridium difficile from the hospital environment. Am J Med 1981;70:906908.
67.Riggs, MM, Sethi, AK, Zabarsky, TF, et al.Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007;45:992998.
68.McFarland, LV, Surawicz, CM, Greenberg, RN, et al.Possible role of cross-transmission between neonates and mothers with recurrent Clostridium difficile infections. Am J Infect Control 1999;27:301303.
69.Kyne, L, Warny, M, Qamar, A, et al.Association between antibody response to toxin A and protection against recurrent Clostridium diffidle diarrhoea. Lancet 2001;357:189193.
70.Sambol, SP, Tang, JK, Merrigan, MM, et al.Infection of hamsters with epidemiologically important strains of Clostridium difficile. J Infect Dis 2001;183:17601766.
71.Anand, A, Bashey, B, Mir, T, et al.Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994;89:519523.
72.Palmore, TN, Sohn, S, Malak, SF, et al.Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26:680684.
73.Chang, H, Parada, J, Evans, C, et al.Onset of symptoms and time to diagnosis of Clostridium difficile diarrhea among outpatients discharged from an acute care hospital [abstract]. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL: 108109.
74.Mayfield, J, McMullen, K, Dubberke, E. Comparison of Clostridium diffidle-associated disease rates using a traditional vs. expanded definition. In: Proceedings of The 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America; March 18-21, 2006; Chicago, IL: 115.
75.Samore, MH, Venkataraman, L, DeGirolami, PC, et al.Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996;100:3240.
76.Mayfield, JL, Leet, T, Miller, J, et al.Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000;31:9951000.
77.Fawley, WN, Wilcox, MH. Molecular epidemiology of endemic Clostridium diffidle infection. Epidemiol Infect 2001;126:343350.
78.Wilcox, MH, Fawley, WN, Wigglesworth, N, et al.Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. J Hosp Infect 2003;54:109114.
79.Brooks, SE, Veal, RO, Kramer, M, et al.Reduction in the incidence of Clostridium diffidle-associated diarrhea in an acute care hospital and a skilled nursing facility following replacement of electronic thermometers with single-use disposables. Infect Control Hosp Epidemiol 1992;13:98103.
80.Pepin, J, Valiquette, L, Alary, ME, et al.Clostridium diffidle-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466472.
81.Johnson, S, Samore, MH, Farrow, KA, et al.Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:16451651.
82.Privitera, G, Scarpellini, P, Ortisi, G, et al.Prospective study of Clostridium difficile intestinal colonization and disease following single-dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother 1991;35:208210.
83.Yee, J, Dixon, CM, McLean, AP, et al.Clostridium difficile disease in a department of surgery: the significance of prophylactic antibiotics. Arch Surg 1991;126:241246.
84.Anand, A, Glatt, AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993;17:109113.
85.Morales Chamorro, R, Serrano Blanch, R, Mendez Vidal, MJ, et al.Pseudomembranous colitis associated with chemotherapy with 5-fluoro-uracil. Clin Transi Oncol 2005;7:258261.
86.Bilgrami, S, Feingold, JM, Dorsky, D, et al.Incidence and outcome of Clostridium difficile infection following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999;23:10391042.
87.Gorschluter, M, Glasmacher, A, Hahn, C, et al.Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001;33:786791.
88.Sanchez, TH, Brooks, JT, Sullivan, PS, et al.Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005;41:16211627.
89.Thibault, A, Miller, MA, Gaese, C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 1991;12:345348.
90.Bliss, DZ, Johnson, S, Savik, K, et al.Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129:10121019.
91.Cunningham, R, Dale, B, Undy, B, et al.Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243245.
92.Dial, S, Alrasadi, K, Manoukian, C, et al.Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171:3338.
93.Al-Jumaili, IJ, Shibley, M, Lishman, AH, et al.Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol 1984;19:7778.
94.Shah, S, Lewis, A, Leopold, D, et al.Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93:175181.
95.McDonald, LC, Coignard, B, Dubberke, E, et al.Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007;28:140145.
96.Cohen, SH, Tang, YJ, Silva, J Jr. Molecular typing methods for the epidemiological identification of Clostridium difficile strains. Expert Rev Moi Diagn 2001;1:6170.
97.Tang, YJ, Houston, ST, Gumerlock, PH, et al.Comparison of arbitrarily primed PCR with restriction endonuclease and immunoblot analyses for typing Clostridium difficile isolates. J Clin Microbiol 1995;33:31693173.
98.Gal, M, Northey, G, Brazier, JS. A modified pulsed-field gel electrophoresis (PFGE) protocol for subtyping previously non—PFGE typeable isolates of Clostridium diffidle polymerase chain reaction ribotype 001. J Hosp Infect 2005;61:231236.
99.Rupnik, M, Avesani, V, Jane, M, et al.A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998;36:22402247.
100.Wullt, M, Burman, LG, Laureil, MH, et al.Comparison of AP-PCR typing and PCR-ribotyping for estimation of nosocomial transmission of Clostridium difficile. J Hosp Infect 2003;55:124130.
101.Northey, G, Gal, M, Rahmati, A, et al.Subtyping of Clostridium difficile PCR ribotype 001 by REP-PCR and PFGE. J Med Microbiol 2005;54:543547.
102.Stubbs, SL, Brazier, JS, O'Neill, GL, et al.PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium diffidle and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999;37:461463.
103.Lemee, L, Bourgeois, I, Ruffin, E, et al.Multilocus sequence analysis and comparative evolution of virulence-associated genes and housekeeping genes of Clostridium difficile. Microbiology 2005;151:31713180.
104.Marsh, JW, O'Leary, MM, Shutt, KA, et al.Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in hospitals. J Clin Microbiol 2006;44:25582566.
105.van den Berg, RJ, Schaap, I, Templeton, KE, et al.Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol 2007;45:10241028.
106.Killgore, G, Thompson, A, Johnson, S, et al.Comparison of seven techniques for typing international epidemic strains of Clostridium difficile. restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 2008;46:431437.
107.Lyras, D, O'Connor, JR, Howarth, PM, et al.Toxin B is essential for virulence of Clostridium diffidle. Nature 2009;458:11761179.
108.Alfa, MJ, Swan, B, VanDekerkhove, B, et al.The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. diffidle panel, EIA for Tox A/B and cytotoxin assays. Diagn Microbiol Infect Dis 2002;43:257263.
109.Fedorko, DP, Engler, HD, O'Shaughnessy, EM, et al.Evaluation of two rapid assays for detection of Clostridium difficile toxin A in stool specimens. J Clin Microbiol 1999;37:30443047.
110.Ticehurst, JR, Aird, DZ, Dam, LM, et al.Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 2006;44:11451149.
111.Planche, T, Aghaizu, A, Holliman, R, et al.Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008;8:777784.
112.Wilcox, MH, Eastwood, KA. Clostridium difficile toxin detection assays. Evaluation report CEP08054. NHS Purchasing and Supplies Agency, Centre for Evidence Based Purchasing, 2009. = %5bMN%5d%5bSP%5d/NHSprocurement/CEP/CEP08054.pdf. Accessed August 14, 2009.
113.Bouza, E, Munoz, P, Alonso, R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005;11(Suppl 4):5764.
114.Kuijper, EJ, van den Berg, RJ, Debast, S, et al.Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006;12:827830.
115.Reller, ME, Lema, CA, Perl, TM, et al.Yield of stool culture with isolate toxin testing versus a two-step algorithm including stool toxin testing for detection of toxigenic Clostridium difficile. J Clin Microbiol 2007;45:36013605.
116.Gerding, DN. Diagnosis of Clostridium difficile-associated disease: patient selection and test perfection. Am J Med 1996;100:485486.
117.Katz, DA, Lynch, ME, Littenberg, B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996;100:487495.
118.Aichinger, E, Schleck, CD, Harmsen, WS, et al.Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008;46:37953797.
119.Larson, HE, Parry, JV, Price, AB, et al.Undescribed toxin in pseudomembranous colitis. Br Med J 1977;1:12461248.
120.Barbut, F, Lalande, V, Burghoffer, B, et al.Prevalence and genetic characterization of toxin A variant strains of Clostridium difficile among adults and children with diarrhea in France. J Clin Miaobiol 2002;40:20792083.
121.Tichota-Lee, J, Jaqua-Stewart, MJ, Benfield, D, et al.Effect of age on the sensitivity of cell cultures to Clostridium difficile toxin. Diagn Microbiol Infect Dis 1987;8:203214.
122.Peterson, LR, Olson, MM, Shanholtzer, CJ, et al.Results of a prospective, 18-month clinical evaluation of culture, cytotoxin testing, and culturette brand (CDT) latex testing in the diagnosis of Clostridium difficile-associated diarrhea. Diagn Microbiol Infect Dis 1988;10:8591.
123.Johnson, S, Kent, SA, O'Leary, KJ, et al.Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001;135:434438.
124.George, WL, Sutter, VL, Citron, D, et al.Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979;9:214219.
125.Wilcox, MH, Fawley, WN, Parnell, P. Value of lysozyme agar incorporation and alkaline thioglycollate exposure for the environmental recovery of Clostridium diffidle. J Hosp Infect 2000;44:6569.
126.Snell, H, Ramos, M, Longo, S, et al.Performance of the Tech Lab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 2004;42:48634865.
127.Zheng, L, Keller, SF, Lyerly, DM, et al.Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol 2004;42:38373840.
128.Barbut, F, Lalande, V, Daprey, G, et al.Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases. Eur J Clin Microbiol Infect Dis 2000;19:481484.
129.Massey, V, Gregson, DB, Chagla, AH, et al.Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. Am J Clin Pathol 2003;119:4549.
130.Sloan, LM, Duresko, BJ, Gustafson, DR, et al.Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium diffidle infection, J Clin Microbiol 2008;46:19962001.
131.Vonberg, RP, Kuijper, EJ, Wilcox, MH, et al.Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008;14(Suppl 5):220.
132.Clabots, CR, Johnson, S, Olson, MM, et al.Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561567.
133.Zafar, AB, Gaydos, LA, Furlong, WB, et al.Effectiveness of infection control program in controlling nosocomial Clostridium difficile. Am J Infect Control 1998;26:588593.
134.Apisarnthanarak, A, Zack, JE, Mayfield, JL, et al.Effectiveness of environmental and infection control programs to reduce transmission of Clostridium difficile. Clin Infect Dis 2004;39:601602.
135.Stone, SP, Berk, V, Quick, A, et al.The effect of an enhanced infection-control policy on the incidence of Clostridium difficile infection and methicillin-resistant Staphyloccocus aureus colonization in acute elderly medical patients. Age Ageing 1998;27:561568.
136.Cartmill, TD, Panigrahi, H, Worsley, MA, et al.Management and control of a large outbreak of diarrhoea due to Clostridium difficile, J Hosp Infect 1994;27:115.
137.Boyce, JM, Pittet, D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm Rep 2002;51:145.
138.Pittet, D, Mourouga, P, Perneger, TV. Compliance with handwashing in a teaching hospital. Infection Control Program. Ann Intern Med 1999;130:126130.
139.Boyce, JM. Using alcohol for hand antisepsis: dispelling old myths. Infect Control Hosp Epidemiol 2000;21:438441.
140.Teare, L, Cookson, B, Stone, S. Hand hygiene. BMJ 2001;323:411412.
141.Wullt, M, Odenholt, I, Walder, M. Activity of three disinfectants and acidified nitrite against Clostridium diffidle spores. Infect Control Hosp Epidemiol 2003;24:765768.
142.Clabots, CR, Gerding, SJ, Olson, MM, et al.Detection of asymptomatic Clostridium difficile carriage by an alcohol shock procedure. J Clin Microbiol 1989;27:23862387.
143.Gordin, FM, Schultz, ME, Huber, RA, et al.Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol 2005;26:650653.
144.Oughton, M, Loo, V, Fenn, S, Lynch, A, Libman, M. Alcohol rub and antiseptic wipes are inferior to soap and water for removal of Clostridium difficile by handwashing. In: Proceedings of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL. Washington, DC: ASM Press; 2007.
145.Bettin, K, Clabots, C, Mathie, P, et al.Effectiveness of liquid soap vs. Chlorhexidine gluconate for the removal of Clostridium difficile from bare hands and gloved hands. Infect Control Hosp Epidemiol 1994;15:697702.
146.Struelens, MJ, Maas, A, Nonhoff, C, et al.Control of nosocomial transmission of Clostridium difficile based on sporadic case surveillance. Am J Med 1991;91:138S144S.
147.Cartmill, TD, Shrimpton, SB, Panigrahi, H, et al.Nosocomial diarrhoea due to a single strain of Clostridium difficile, a prolonged outbreak in elderly patients. Age Ageing 1992;21:245249.
148.Lai, KK, Melvin, ZS, Menard, MJ, et al.Clostridium difficile-associated diarrhea: epidemiology, risk factors, and infection control, infect Control Hosp Epidemiol 1997;18:628632.
149.Garner, JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1996;17:5380.
150.Johnson, S, Gerding, DN, Olson, MM, et al.Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990;88:137140.
151.Perry, C, Marshall, R, Jones, E. Bacterial contamination of uniforms. J Hosp Infect 2001;48:238241.
152.Berild, D, Smaabrekke, L, Halvorsen, DS, et al.Clostridium difficile infections related to antibiotic use and infection control facilities in two university hospitals. J Hosp infect 2003;54:202206.
153.Dettenkofer, M, Seegers, S, Antes, G, et al.Does the architecture of hospital facilities influence nosocomial infection rates? A systematic review. Infect Control Hosp Epidemiol 2004;25:2125.
154.The American Institute of Architects Academy of Architecture for Health and the Facilities Guidelines Institute. Guidelines for design and construction of health care facilities. Washington, DC: American Institute of Architects Press, 2006.
155.Strimling, MO, Sacho, H, Berkowitz, I. Clostridium difficile infection in health-care workers. Lancet 1989;2:866867.
156.Arfons, L, Ray, AJ, Donskey, CJ. Clostridium difficile infection among health care workers receiving antibiotic therapy. Clin Infect Dis 2005;40:13841385.
157.Cohen, RS, DiMarino, AJ Jr, Allen, ML. Fecal Clostridium difficile carriage among medical housestaff. N J Med 1994;91:327330.
158.Brown, E, Talbot, GH, Axelrod, P, et al.Risk factors for Clostridium difficile toxin-associated diarrhea, infect Control Hosp Epidemiol 1990 11:283290.
159.Delmee, M, Vandercam, B, Avesani, V, et al.Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol 1987;6:623627.
160.Bender, BS, Bennett, R, Laughon, BE, et al.Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986;2:1113.
161.Johnson, S, Homann, SR, Bettin, KM, et al.Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 1992;117:297302.
162.Hota, B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis 2004;39:11821189.
163.O'Neill, G, Adams, JE, Bowman, RA, et al.A molecular characterization of Clostridium diffidle isolates from humans, animals and their environments. Epidemiol Infect 1993;111:257264.
164.Kim, KH, Fekety, R, Batts, DH, et al.Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis 1981;143:4250.
165.Fawley, WN, Underwood, S, Freeman, J, et al.Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol 2007;28:920925.
166.Manian, FA, Meyer, L, Jenne, J. Clostridium difficile contamination of blood pressure cuffs: a call for a closer look at gloving practices in the era of universal precautions. Infect Control Hosp Epidemiol 1996;17:180182.
167.Brooks, S, Khan, A, Stoica, D, et al.Reduction in vancomycin-resistant Enterococcus and Clostridium difficile infections following change to tympanic thermometers. Infect Control Hosp Epidemiol 1998;19:333336.
168.Jernigan, JA, Siegman-Igra, Y, Guerrant, RC, et al.A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol 1998;19:494-49.
169.Kaatz, GW, Gitlin, SD, Schaberg, DR, et al.Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988;127:12891294.
170.Boyce, JM, Havill, NL, Otter, JA, et al.Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol 2008;29:723729.
171.Rutala, WA, Gergen, MF, Weber, DJ. Inactivation of Clostridium difficile spores by disinfectants. Infect Control Hosp Epidemiol 1993;14:3639.
172.Block, C. The effect of Perasafe and sodium dichloroisocyanurate (NaDCC) against spores of Clostridium diffidle and Badllus atrophaeus on stainless steel and polyvinyl chloride surfaces. J Hosp Infect 2004;57:144148.
173.Perez, J, Springthorpe, VS, Sattar, SA. Activity of selected oxidizing microbicides against the spores of Clostridium diffidle-. relevance to environmental control. Am J Infect Control 2005;33:320325.
174.Chang, HT, Krezolek, D, Johnson, S, et al.Onset of symptoms and time to diagnosis of Clostridium difficile-associated disease following discharge from an acute care hospital. Infect Control Hosp Epidemiol 2007;28:926931.
175.McFarland, LV, Surawicz, CM, Stamm, WE. Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 1990;162:678684.
176.Wistrom, J, Norrby, SR, Myhre, EB, et al.Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001;47:4350.
177.Bignardi, GE. Risk factors for Clostridium diffidle infection. J Hosp Infect 1998;40:115.
178.Davey, P, Brown, E, Fenelon, L, et al.Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2005;19:CD003543.
179.Pear, SM, Williamson, TH, Bettin, KM, et al.Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994;120:272277.
180.Climo, MW, Israel, DS, Wong, ES, et al.Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium diffidle-associzted diarrhea and cost. Ann Intern Med 1998;128:989995.
181.Carling, P, Fung, T, Killion, A, et al.Favorable impact of a multidisci-plinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003;24:699706.
182.McNulty, C, Logan, M, Donald, IP, et al.Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 1997;40:707711.
183.Khan, R, Cheesbrough, J. Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital. J Hosp Infed 2003;54:104108.
184.Wilcox, MH, Freeman, J, Fawley, W, et al.Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;54:168172.
185.Alston, WK, Ahem, JW. Increase in the rate of nosocomial Clostridium diffidle-associated diarrhoea during shortages of piperacillin-tazobactam and piperacillin. J Antimicrob Chemother 2004;53:549550.
186.Valiquette, L, Cossette, B, Garant, MP, et al.Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associzted disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45(Suppl 2):S112S121.
187.Gaynes, R, Rimland, D, Killum, E, et al.Outbreak of Clostridium diffidle infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004;38:640645.
188.Biller, P, Shank, B, Lind, L, et al.Moxifloxacin therapy as a risk factor for Clostridium difficile-associzted disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28:198201.
189.Hickson, M, D'Souza, AL, Muthu, N, et al.Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007;335:80.
190.Teasley, DG, Gerding, DN, Olson, MM, et al.Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2:10431046.
191.Wenisch, C, Parschalk, B, Hasenhundl, M, et al.Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium diffidle-associated diarrhea. Clin Infect Dis 1996;22:813818.
192.Wullt, M, Odenholt, I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium diffidle-associated diarrhoea. J Antimicrob Chemother 2004;54:211216.
193.Bricker, E, Garg, R, Nelson, R, Loza, A, Novak, T, Hansen, J. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005(1):CD004610.
194.Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44(RR-12):113.
195.Fekety, R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:739750.
196.Bolton, RP, Culshaw, MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986;27:11691172.
197.Keighley, MR, Burdon, DW, Arabi, Y, et al.Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ 1978;2:16671669.
198.Baird, DR. Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile. J Antimicrob Chemother 1989;23:167169.
199.Olsson-Liljequist, B, Nord, CE. In vitro susceptibility of anaerobic bacteria to nitroimidazoles. Scand J Infect Dis Suppl 1981;26:4245.
200.Wong, SS, Woo, PC, Luk, WK, et al.Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34:16.
201.Freeman, J, Stott, J, Baines, SD, et al.Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother 2005;56:988989.
202.Drummond, LJ, McCoubrey, J, Smith, DG, et al.Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric inpatients over an 18-month period. J Med Microbiol 2003;52:259263.
203.Aspevall, O, Lundberg, A, Burman, LG, et al.Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 2006;50:18901892.
204.Pelaez, T, Alcala, L, Alonso, R, et al.In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005;49:11571159.
205.Baines, SD, O'Connor, R, Freeman, J, et al.Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62:10461052.
206.Musher, DM, Aslam, S, Logan, N, et al.Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:15861590.
207.Bishara, J, Bloch, Y, Garty, M, et al.Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 2006;54:141144.
208.Lamontagne, F, Labbe, AC, Haeck, O, et al.Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007;245:267272.
209.Belmares, J, Gerding, DN, Parada, JP, et al.Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect 2007;55:495501.
210.Pepin, J, Valiquette, L, Gagnon, S, et al.Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP 1/027. Am J Gastroenterol 2007;102:27812788.
211.Zar, FA, Bakkanagari, SR, Moorthi, KM, et al.A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302307.
212.Louie, T, Gerson, M, Grimard, D, et al.Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). In: Proceedings of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL. Washington, DC: ASM Press; 2007. Abstract K-425a
213.Apisarnthanarak, A, Razavi, B, Mundy, LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002;35:690696.
214.McPherson, S, Rees, CJ, Ellis, R, et al.Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006;49:640645.
215.Longo, WE, Mazuski, JE, Virgo, KS, et al.Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum 2004;47:16201626.
216.Bartlett, JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984;6(Suppl 1):S235S241.
217.Bartlett, JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992;15:573581.
218.Barbut, F, Richard, A, Hamadi, K, et al.Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38:23862388.
219.Johnson, S, Adelmann, A, Clabots, CR, et al.Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 1989;159:340–33.
220.Pepin, J, Saheb, N, Coulombe, MA, et al.Emergence of fluoroquinolones as the predominant risk factor for Clostridium diffidle-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:12541260.
221.Nair, S, Yadav, D, Corpuz, M, et al.Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am J Gastroenterol 1998;93:18731876.
222.Pepin, J, Routhier, S, Gagnon, S, et al.Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758764.
223.Kapoor, K, Chandra, M, Nag, D, et al.Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 1999;19:8388.
224.Lagrotteria, D, Holmes, S, Smieja, M, et al.Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006;43:547552.
225.Johnson, S, Schriever, C, Galang, M, et al.Interruption of recurrent Clostridium diffidle-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846848.
226.Curry, SR, Marsh, JW, Shutt, KA, et al.High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48:425429.
227.Enache-Angoulvant, A, Hennequin, C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005;41:15591568.
228.Dendukuri, N, Costa, V, McGregor, M, et al.Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005;173:167170.
229.Gustafsson, A, Lund-Tonnesen, S, Berstad, A, et al.Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998;33:721727.
230.Aas, J, Gessert, CE, Bakken, JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36:580585.
231.Giannasca, PJ, Warny, M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 2004;22:848856.
232.Wilcox, MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004;53:882884.
233.Salcedo, J, Keates, S, Pothoulakis, C, et al.Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366370.

Related content

Powered by UNSILO

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

  • Stuart H. Cohen (a1), Dale N. Gerding (a2), Stuart Johnson (a2), Ciaran P. Kelly (a3), Vivian G. Loo (a4), L. Clifford McDonald (a5), Jacques Pepin (a6) and Mark H. Wilcox (a7)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.